Skip to main content
SpringerLink
Log in

Active surveillance for low-risk prostate cancer in Austria: the online registry of the Qualitätspartnerschaft Urologie (QuapU)

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Background

Active surveillance (AS) is a well-recognized strategy to reduce the risk of overtreatment in men with low-risk prostate cancer. No data on this approach are available from Austria.

Methods

The Qualitätspartnerschaft Urologie (QuapU) developed an online database for patients managed with AS in Austria. Principal inclusion/exclusion criteria corresponded to those of the S3 prostate cancer guideline of German urologists: prostate-specific antigen (PSA) <10 ng/ml, Gleason score <7 (maximum 20% of biopsies being positive). Control visits were scheduled at 3‑month intervals, control biopsies were scheduled at 12 and 36 months.

Results

To date 131 patients have been entered into this data base. Mean patient age is 64 years, 6% were younger than 50 years, two thirds of patients were aged 50–70 years and 25% were older than 70 years. Mean PSA value was 5.9 ng/ml (PSA 0–4 ng/ml: 15%; PSA >4–10 ng/ml: 85%). The prostate volume averaged 39 ml. The mean time under AS was 17.5 months (<12 months: 60%; >12 months: 40%). The AS adherence at 12 months was 85% and at 24 months 76%. To date, a total of 23 patients (17.6%) stopped AS. The most frequent reasons for discontinuing AS were patient wish for active treatment (43.5%) and PSA progression (30.4%). A histological progression was rarely seen (6.1%) and the control biopsy rate was low (19.8%).

Conclusion

This study is the first description of AS in Austria and documents the feasibility of an online registry for AS. The data confirm the international experience with this approach with acceptable adherence rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chung MS, Lee SH. Current status of active surveillance in prostate cancer. Investig Clin Urol. 2016;57:14–20.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.

    Article  PubMed  Google Scholar 

  3. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–32.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent – update 2013. Eur Urol. 2014;65(1):124–37.

    Article  PubMed  Google Scholar 

  5. AUA Prostate Cancer Clinical Guideline Update Pane, Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.

    Article  Google Scholar 

  6. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. Leitlinienprogramm Onkologie: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 3.1,2014 AWMF Registernummer: 034/022OL 2014. http://leitlinienprogrammonkologie.de/Leitlinien.7.0.html. Accessed 1.9.2016.

    Google Scholar 

  7. Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190:1742–9.

    Article  PubMed  Google Scholar 

  8. Bokhorst LP, Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ, PRIAS study group. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70(6):954–60. doi:10.1016/j.eururo.2016.06.007.

    Article  PubMed  Google Scholar 

  9. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272–7.

    Article  PubMed  Google Scholar 

  10. Tosoian JT, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. Active surveillance program for prostate cancer: an update of the John Hopkins experience. J Clin Oncol. 2011;29:2185–90.

    Article  PubMed  Google Scholar 

  11. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring on active surveillance minimizes the need for treatment. Eur Urol. 2010;58:831–5.

    Article  PubMed  Google Scholar 

  12. Van den Bergh RCN, Roemeling S, Robol MJ, Aus G, Hugosson J, Rannikkko AS, Tammela TL, Bangma CH, Schröder FH. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55:1–8.

    Article  PubMed  Google Scholar 

  13. Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664–70.

    Article  PubMed  Google Scholar 

  14. Cristea O, Lavallee LT, Montroy J, Stokl A, Cnossen S, Mallick R, et al. Active surveillance in Canadian men with low-grade prostate cancer. CMAJ. 2016;188:E141–E147.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monographs. 2012;45:202–6.

    Article  Google Scholar 

  16. Lelly SP, Van Den Eeden SK, Hoffman RM, Aaronson DS, Lobo T, Luta G, et al. Sociodemographic and clinical predictors of switching to active treatment among a large, ethnically diverse cohort of men with low risk prostate cancer on observational management. J Urol. 2016;196(3):734–40. doi:10.1016/j.juro.2016.04.045.

    Article  Google Scholar 

  17. Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations – a report of a European School of Oncology task force. Eur Urol. 2016; doi:10.1016/j.eururo.2016.06.011.

    Google Scholar 

  18. Kim TH, Jeong JY, Lee SW, Kim CK, Park BK, Sung HH, et al. Diffusion-weigthed magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance. Eur Radiol. 2015;25:1786–92.

    Article  PubMed  Google Scholar 

  19. Mullins JK, Bonekamp D, Landis P, Begun H, Partin AW, Epstein JL, et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int. 2013;111:1037–45.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the following members (in the rank of recruited patients) of the QuapU (Austrian urologists) who have recruited >3 patients to this registry: Weinkammer Martin, Kozak Walter, Pferschy Jürgen, Dorfinger Karl, Schlögl Peter, Schobersberger Johannes, Budinsky Michael, Sollner Kurt, Huber Erik, Kerbl Kurt, and Hofer Wilhelm.

Author information

Authors and Affiliations

  1. Department of Urology, Kaiser-Franz-Josef Spital, Kundratstrasse 3, 1100, Vienna, Austria

    Klaus Eredics & Stephan Madersbacher

  2. Urological Practice, Vienna, Austria

    Karl Dorfinger

  3. Department of Urology, Medical University of Vienna, Vienna, Austria

    Gero Kramer

  4. Department of Urology, Krankenhaus der Barmherzigen Brüder, Vienna, Austria

    Anton Ponholzer

Authors
  1. Klaus Eredics
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl Dorfinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gero Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anton Ponholzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephan Madersbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Madersbacher.

Ethics declarations

Conflict of interest

K. Eredics, K. Dorfinger, G. Kramer, A. Ponholzer, and S. Madersbacher declare that they have no competing interests.

Additional information

Klaus Eredics, Karl Dorfinger, Gero Kramer, Anton Ponholzer, and Stephan Madersbacher represent the Qualitätspartnerschaft Urologie.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eredics, K., Dorfinger, K., Kramer, G. et al. Active surveillance for low-risk prostate cancer in Austria: the online registry of the Qualitätspartnerschaft Urologie (QuapU). Wien Klin Wochenschr 129, 375–379 (2017). https://doi.org/10.1007/s00508-016-1149-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-016-1149-8

Keywords

Search

Navigation